medline.ch Urologie-Nephrologie Tumoren BPH

	Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma. J Immunother Cancer Xu W, Lu J, Liu WR, Anwaier A, Wu Y, Tian X, Su JQ, Qu YY, Yang J, Zhang H, Ye D. PMID: 38040418 [PubMed - in process]
	Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis. Biochim Biophys Acta Rev Cancer Li S, Kang Y, Zeng Y. PMID: 38040267 [PubMed - as supplied by publisher]
	Risk factors for prostate cancer in men with false-negative mpMRI: A retrospective single center cohort study of image quality scores and clinical parameters. Eur J Radiol Pausch AM, Ghafoor S, Kluckert J, Rupp NJ, Eberli D, Hötker AM. PMID: 38039782 [PubMed - as supplied by publisher]
	A case report of liver infiltration from a large renal cell carcinoma: Diagnostic and management enigma. Int J Surg Case Rep Choudhary D, Naik M, Vageesh BG, Agarwal A. PMID: 38039569 [PubMed - as supplied by publisher]
	Assessment of quantitative zonal parameters of prostate gland in discrimination of normal, benign, and malignant conditions: are these the more reliable parameters in the diagnosis of prostate cancer? Eur Rev Med Pharmacol Sci Karaca L, Özdemir ZM, Kahraman A, Çelik H, Kaya S. PMID: 38039044 [PubMed - in process]
	Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer. JAMA Netw Open Ma TM, Agarwal N, Mahal B, Barragan-Carrillo R, Spratt D, Rettig MB, Valle LF, Steinberg ML, Garraway I, Vapiwala N, Xiang M, Kishan AU. PMID: 38039002 [PubMed - in process]
	Recurrent prostate cancer: combined role for MRI and PSMA-PET in (68)Ga-PSMA-11 PET/MRI. Eur Radiol Jannusch K, Bruckmann NM, Morawitz J, Boschheidgen M, Quick HH, Herrmann K, Fendler WP, Umutlu L, Stuschke M, Hadaschik B, Antoch G, Schimmöller L, Kirchner J. PMID: 38038758 [PubMed - as supplied by publisher]
	Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Cancer Med Hannouneh ZA, Hijazi A, Alsaleem AA, Hami S, Kheyrbek N, Tanous F, Khaddour K, Abbas A, Alshehabi Z. PMID: 38037752 [PubMed - as supplied by publisher]
	A Notch signaling-related lncRNA signature for predicting prognosis and therapeutic response in clear cell renal cell carcinoma. Sci Rep Zhang L, Li Y, Cai B, Chen J, Zhao K, Li M, Lang J, Wang K, Pan S, Zhu K. PMID: 38036719 [PubMed - in process]
	Moving forward through consensus: a national Delphi approach to determine the top research priorities in prostate cancer in Uganda. BMJ Open Ssemata AS, Muhumuza R, Seeley J, Lombe DC, Mwamba M, Msadabwe S, Mwaka AD, Aggarwal A. PMID: 38035740 [PubMed - in process]
	Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives. Cancer Genomics Proteomics Costagliola A, Lombardi R, Liguori G, Morrione A, Giordano A. PMID: 38035703 [PubMed - in process]
	Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer. Cancer Treat Rev Efstathiou JA, Morgans AK, Bland CS, Shore ND. PMID: 38035646 [PubMed - as supplied by publisher]
	Redo nephron-sparing surgery in stage V pediatric renal tumors - A report from the SIOP/GPOH study group for renal tumors. Eur J Surg Oncol Fuchs J, Schunn MC, Schäfer JF, Ebinger M, Graf N, Furtwängler R, Warmann SW. PMID: 38035461 [PubMed - as supplied by publisher]
	OSM May Serve as a Biomarker of Poor Prognosis in Clear Cell Renal Cell Carcinoma and Promote Tumor Cell Invasion and Migration. Int J Genomics Wei S, Chen Y, Shi X, Zuo L, Zhang L. PMID: 38034950 [PubMed]
	Evaluation of proteolytic activity and serine proteases distribution in plasma from patients with bladder cancer. Front Med (Lausanne) Synelnyk T, Vovk T, Halenova T, Tytarenko V, Raksha N, Savchuk O, Falalyeyeva T, Ostapchenko L, Yakovlev P, Kozyk M, Thorley D, Strubchevska K. PMID: 38034543 [PubMed]
	Circadian Clock Dysregulation and Prostate Cancer: A Molecular and Clinical Overview. Clin Med Insights Oncol Kaakour D, Fortin B, Masri S, Rezazadeh A. PMID: 38033743 [PubMed]
	Association of obesity and different metabolic status with prognosis in patients with bladder cancer: a retrospective cohort study. Ther Adv Urol Dong Y, Cheng Y, Guo H, Sun J, Han J, Zhong F, Li Q, Wang D, Chen W, Fan X, Zhao J. PMID: 38033708 [PubMed]
	Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer - a narrative review. Front Oncol Szponar P, Petrasz P, Brze, Drewa T, Zorga P, Adamowicz J. PMID: 38033494 [PubMed]
	A Systems Biology Approach for Investigating Significant Biomarkers and Drug Targets Common Among Patients with Gonorrhea, Chlamydia, and Prostate Cancer: A Pilot Study. Bioinform Biol Insights Noman AA, Islam MK, Feroz T, Hossain MM, Shakil MSK. PMID: 38033384 [PubMed]
	Zero ischemia robotic partial nephrectomy: Oncological and functional outcomes of a multicenter study. Turk J Med Sci Ener K, Canda AE, Binbay M, Balbay MD, Atmaca AF. PMID: 38031944 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 166194

Seite 1 von 8310



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung